Advanced Cholangiocarcinoma Clinical Trials

20 clinical trials for Advanced Cholangiocarcinoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement — RECRUITING · PHASE2
• Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion — RECRUITING · PHASE1
• AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease — RECRUITING · PHASE1
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer — RECRUITING · PHASE2
• Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma — RECRUITING · PHASE2
• Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma — RECRUITING · PHASE3
• Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — OTHER
• Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations — NOT_YET_RECRUITING · PHASE3
• NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma — TERMINATED · PHASE1
• A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping — NOT_YET_RECRUITING
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — TERMINATED · PHASE3
• Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) — COMPLETED · PHASE3
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — TERMINATED · PHASE3
• Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma — TERMINATED · PHASE1
• A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma — TERMINATED · PHASE2
• IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 — OTHER · PHASE1
• Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron — TERMINATED · PHASE2
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma — OTHER · PHASE1
• Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma — OTHER · PHASE2
• Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer — TERMINATED · PHASE1

Refine this search